Getinge announces Eric Honroth departure as Getinge stock costs EUR 22.32
Published on 10/08/2026 at 18:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Getinge announced on October 7, 2026 that Eric Honroth will leave as President Life Science on October 31.
- Getinge's second-quarter 2026 revenue reached SEK 8.381 billion and net income SEK 841.0 million.
- Getinge stock was trading at EUR 22.32 at Lang & Schwarz on October 8, 2026, down 0.13 percent versus EUR 22.35.
- The next reporting date is October 20, 2026, while interim Life Science leadership starts on November 1, 2026.
After-hours trading put Getinge stock (ISIN SE0000202624) at EUR 22.32 on October 8, 2026, down 0.13 percent versus the EUR 22.35 prior close at Lang & Schwarz. According to Getinge on October 7, 2026, Eric Honroth will leave his role as President Life Science on October 31, with an internal leader becoming acting president on November 1.
Three milestones shape the stock
Getinge's second-quarter 2026 results set the financial baseline. Simply Wall St reported on October 2, 2026 that revenue reached SEK 8.381 billion, up from SEK 8.238 billion in the second quarter of 2025, while net income rose to SEK 841.0 million from SEK 524.0 million. Net margin increased to 10.0 percent from 6.4 percent.
On September 24, 2026, MarketScreener reported that SEB raised its target for Getinge from SEK 262.00 to SEK 280.00 and maintained a Buy rating. The target increase followed an earlier September 7, 2026 upgrade by ABG Sundal Collier from Hold to Buy with a SEK 285.00 target, as reported in the same MarketScreener overview.
What does the margin signal?
The second-quarter 2026 margin improvement carried an important qualification. Yahoo Finance reported that adjusted EBITA margin reached 17.6 percent, helped by a tariff refund, while organic net sales grew 4.6 percent and organic order intake increased 6.2 percent. Management reiterated 2026 organic net sales growth guidance of 3.0 percent to 5.0 percent.
Dates investors can track
The next scheduled reporting date is October 20, 2026, when Getinge is listed as due to publish its third-quarter 2026 results in the MarketScreener calendar. October 31, 2026 is the announced departure date for Honroth, followed by the interim appointment on November 1, 2026.
Getinge stock stays near yearly high
Getinge stock was trading at EUR 22.32 at Lang & Schwarz on October 8, 2026 at 6:37 p.m. CEST, down 0.13 percent versus the EUR 22.35 prior close dated October 7, 2026. The primary listing is Nasdaq Stockholm, where the finance quote showed SEK 249.60 on October 8, 2026, against a 52-week range of SEK 175.90 to SEK 254.10 and market capitalization of SEK 68.0 billion. The euro quote stood 12.03 percent below the 52-week high only when compared within the same currency, so the foreign-currency range is kept separate from the Lang & Schwarz reference price. The further course of trading is shown by the continuously updated real-time quote of Getinge B stock.
Getinge B market facts
- Company: Getinge AB (publ)
- ISIN: SE0000202624
- Ticker: GETI B
- Primary exchange: Nasdaq Stockholm
- Price Lang & Schwarz as of October 8, 2026, 6:37 p.m. CEST: EUR 22.32
- Change versus prior close: minus 0.13 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 22.35
- Market capitalization: SEK 68.0 billion as of October 8, 2026
- 52-week range: SEK 175.90-254.10 as of October 8, 2026
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report OMXS30.
